Evidence map›Paper›PMID 37631329›Full record

ArticlePharmaceutics2023

Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy.

Tuong Ngoc-Gia Nguyen, Cuong Viet Pham, Rocky Chowdhury, Shweta Patel, Satendra Kumar Jaysawal, Yingchun Hou, Huo Xu, Lee Jia, Andrew Duan, Phuong Ha-Lien Tran and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tuong Ngoc-Gia NguyenSchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.ORCID 0000-0001-5198-7990
Cuong Viet PhamSchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.ORCID 0000-0001-6106-6685
Rocky ChowdhurySchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.ORCID 0000-0001-8957-7962
Shweta PatelSchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.
Satendra Kumar JaysawalSchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.
Yingchun HouLaboratory of Tumor Molecular and Cellular Biology, College of Life Sciences, Shaanxi Normal University, 620 West Chang'an Avenue, Xi'an 710119, China.
Huo XuCollege of Materials and Chemical Engineering, Minjiang University, Fuzhou 350108, China.
Lee JiaCollege of Materials and Chemical Engineering, Minjiang University, Fuzhou 350108, China.
Andrew DuanSchool of Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3800, Australia.
Phuong Ha-Lien TranSchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.
Wei DuanSchool of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, there has been a significant expansion in the development of plant-derived extracellular nanovesicles (EVs) as an effective drug delivery system for precision therapy. However, the lack of effective methods for the isolation and characterization of plant EVs hampers progress in the field. To solve a challenge related to systemic separation and characterization in the plant-derived EV field, herein, we report the development of a simple 3D inner filter-based method that allows the extraction of apoplastic fluid (AF) from blueberry, facilitating EV isolation as well as effective downstream applications. Class I chitinase (PR-3) was found in blueberry-derived EVs (BENVs). As Class I chitinase is expressed in a wide range of plants, it could serve as a universal marker for plant-derived EVs. Significantly, the BENVs exhibit not only higher drug loading capacity than that reported for other EVs but also possess the ability to modulate the release of the proinflammatory cytokine IL-8 and total glutathione in response to oxidative stress. Therefore, the BENV is a promising edible multifunctional nano-bio-platform for future immunomodulatory therapies.

Indexed as

biomarkerclass I chitinasedrug deliveryimmunomodulatorypathogen-related proteinsplant EV

Identifiers

PMID37631329
PMCPMC10458573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.